Preferential HDAC6 inhibitors derived from HPOB exhibit synergistic antileukemia activity in combination with decitabine

• DOI: 10.26434/chemrxiv-2024-flvmf-v2
• Publication Date: 2024-04-22T06:10:35Z
• Authors: Maik Tretbar; Julian Schliehe-D...; Lukas von Bredow; Kathrin Tan; Martin Roatsch; Jia-Wey Tu; Marie Kemkes; Melf Sönnichsen; Andrea Schöler; Arndt Borkhardt; Sanil Bhatia; Finn Kristian Hansen
• Keywords: 0303 health sciences; 03 medical and health sciences

Histone deacetylase 6 (HDAC6) is an emerging drug target to treat oncological and non-oncological conditions. Since highly selective HDAC6 inhibitors display limited anticancer activity when used as single agent, they usually require combination therapies with other chemotherapeutics. In this work, we synthesized a mini library of analogues of the preferential HDAC6 inhibitor HPOB in only two steps via an Ugi four-component reaction as the key step. Biochemical HDAC inhibition and cell viability assays led to the identification of 1g (highest antileukemic activity) and 2b (highest HDAC6 inhibition) as hit compounds. In subsequent combination screens, both 1g and especially 2b showed synergy with DNA methyltransferase inhibitor decitabine in acute myeloid leukemia (AML). Our findings highlight the potential of combining HDAC6 inhibitors with DNA methyltransferase inhibitors as a strategy to improve AML treatment outcomes.